HelmyMGuirgisMD

Oncology • Dana Point, CA

Cutaneous Lymphoma, Hematologic Oncology

Physician

Join to view full profile

Dr. Guirgis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Guirgis' full profile

Already have an account?

Office
24806 Sea Crest Dr
Dana Point, CA 92629
Phone+1 949-306-7157

Fax+1 949-493-7775

Summary

Drug Costs vs Probability of Survival in Lung Cancer: Impact of Dosage, Duration

Abstract: Clinical guidelines and pathways recommend use of immune checkpoint inhibitors (ICI) in first- and second-line treatment of advanced/metastatic non-sm

The impact of PD-L1 on survival and value of the immune check point inhibitors i

The impact of programmed death receptor-ligand1 (PD-L1) on costs and value of the immune check point inhibitors (ICPI) has received minimal attention. Objective

Education & Training

University of California (Irvine)Fellowship, Hematology and Medical Oncology, 1979 - 1980
City of Hope National Medical CenterFellowship, Hematology and Medical Oncology, 1978 - 1979
Mount Sinai Hospital Medical Center of ChicagoResidency, Internal Medicine, 1976 - 1978
Creighton University School of Medicine (Omaha)Internship, Internal Medicine, 1975 - 1976
Creighton University School of MedicineClass of 1975

Certifications & Licensure

IL State Medical License 1976 - Present
CA State Medical License 1978 - 2025
CT State Medical License 2003 - 2003
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

14 citations
The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective.
Helmy M. Guirgis
Journal for Immunotherapy of Cancer. 2018-02-20
12 citations
The value of anticancer drugs in metastatic castrate-resistant prostate cancer: economic tools for the community oncologist.
Helmy M. Guirgis
The Journal of Community and Supportive Oncology. 2015-10-01
6 citations
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Helmy M. Guirgis
Journal of Oncology Practice. 2012-07-01

Lectures

Costs and hazard ratios of commonly used drugs in advanced/metastatic lung cancer at Cancer Free Foundation, Dana Point, California.
2019 ASCO Annual Meeting - 6/1/2019

Committees

Member, Tunor Boards in various hospitals in Orange County,CA 1985 - 2013

Research History

Development of methodology to evaluate value of anticancer drugsAuthored various manuscripts and abstracts on cost of anticancer drugs and survival.1995 - Present